DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Baltimore Marriott Waterfront

2022 年 01 月 24 日 8:00 上午 - 2022 年 01 月 26 日 5:00 下午

700 Aliceanna Street , Baltimore, MD 21202

DIA Global Pharmacovigilance and Risk Management Strategies Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

概览

Short Course
Conference: January 24-26

Safety monitoring of medicines is imperative for ensuring health and wellbeing of patients worldwide. For pharmacovigilance professionals, the complexity of safety and pharmacovigilance efforts is heightened by the rapid development of multiple vaccines and treatments, the emergent nature of knowledge about the etiology of the corona virus disease, and pervasive misinformation about prevention and treatment practices. The current challenges are ongoing and will have lasting impact on safety, pharmacovigilance, and other related PV activities, such as risk management.

DIA's Global Pharmacovigilance and Risk Management Strategies Conference provides the foundation for strong strategic planning and practical decision-making in pharmacovigilance programs. Developed by recognized experts from the biopharmaceutical industry and global regulatory agencies, this conference provides the background, context, and opportunities to discuss current challenges and to problem-solve around issues that matter most to professionals working in the field.

For this year’s program, stakeholders from medicines research, global regulation, and healthcare will join to analyze the challenges for safety and pharmacovigilance efforts in this uncertain environment and examine effective strategies for addressing gaps and needs. New approaches and collaborations that build on the foundation of sound pharmacovigilance principles to optimize safety and pharmacovigilance practice and ensure safe medicines for patients will be explored, in a global and regional context.

Social distancing measures may be in place at the time of the event. Therefore, we encourage you to register and make your housing arrangements early due to potential limited capacity. If the capacity limit is reached, we will only be able to offer the virtual option. Don’t miss out on your chance to meet live again with your friends and colleagues!

Featured

Want to learn more about DIA Global Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!

Continuing Education

Highlights & Features

Short Course or Primer

To keep you at the forefront.

2022 年 01 月 10 日

Short Course 1:

Reference Safety Information

2022 年 01 月 12 日

Short Course 2:

Aggregate Safety Assessments

2022 年 01 月 14 日

Short Course 3:

Getting Real About Inspections

项目委员会

  • Stephen  Knowles, MD, MRCP
    Stephen Knowles, MD, MRCP Chief Medical Officer
    Halozyme Therapeutics, United States
  • Annette S. Williams, MBA, RPh
    Annette S. Williams, MBA, RPh Vice President, Pharmacovigilance
    IQVIA, United States
  • Mariette  Boerstoel-Streefland, MD, MBA, MS
    Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Patient Safety Officer
    Bristol Myers Squibb, United States
  • James  Buchanan, PharmD
    James Buchanan, PharmD President
    Covilance LLC, United States
  • Cheryl  Campbell, MS
    Cheryl Campbell, MS Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
    FDA, United States
  • E. Stewart  Geary, MD
    E. Stewart Geary, MD MD, Global Safety Officer
    Eisai Co., Ltd., Japan
  • Jeremy  Jokinen, PhD, MS
    Jeremy Jokinen, PhD, MS Vice President and Head Global Patient Safety
    Argenx, United States
  • Jamie Ridley Klucken, PharmD, MBA, RPh
    Jamie Ridley Klucken, PharmD, MBA, RPh Safety Evaluator, Division of Pharmacovigilance, OSE, CDER
    FDA, United States
  • Linda J. Scarazzini, MD, RPh
    Linda J. Scarazzini, MD, RPh Vice President, Pharmacovigilance and Patient Safety
    AbbVie, United States
  • Sarah  Vaughan
    Sarah Vaughan Head of Vigilance Operations
    Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
  • Annette  Stemhagen, DrPH, PhD, FISPE
    Annette Stemhagen, DrPH, PhD, FISPE Chief Science Officer
    UBC, United States
  • Jo  Wyeth, PharmD
    Jo Wyeth, PharmD Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
    FDA, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。